clopidogrel + ticagrelor (AstraZeneca)

Clopidogrel and ticagrelor are P2Y12 receptor inhibitors used as antiplatelet agents in the management of coronary artery disease (CAD) and acute coronary syndrome (ACS), particularly following percutaneous coronary intervention (PCI). Clopidogrel is a thienopyridine prodrug that requires hepatic activation to irreversibly inhibit the P2Y12 receptor, whereas ticagrelor is a cyclopentyltriazolopyrimidine that directly and reversibly inhibits the same receptor. This specific entry highlights a clinical investigation by Wroclaw Medical University (NCT03143088) exploring the impact of these agents on central and peripheral chemosensitivity to better understand the mechanism of ticagrelor-induced dyspnea, a common side effect that occurs more frequently with ticagrelor than with clopidogrel.

Brand names

PlavixBrilintaPossia

Other names

P2Y12 inhibitorsP-2Y12 inhibitorsP 2Y12 inhibitors